Retatrutide: Telehealth companies are offering it. What do Lilly and the FDA have to say about it?

By Peptide Policy Watch editorial team · Published October 29, 2026

A laptop showing a blurred video call on a wooden desk next to a plain white box topped with two small clear vials and a blue cold pack.

The pitch on one Texas clinic's retatrutide page, as quoted in a federal lawsuit filed October 8, 2026, was aimed at a very specific person: someone "who ha[s] plateaued on another GLP-1 medication." [V] It's a real audience. Millions of people now know their way around semaglutide and tirzepatide, and many have read about the drug Lilly's trials put in a class of its own. The catch is that the drug in those trials isn't approved, isn't allowed in compounding, and isn't Lilly's to share outside a study yet. So what are these online clinics, med spas and telehealth sites actually offering, and what are regulators doing about it?

Facts are as of October 29, 2026. Sources, with retrieval dates, are at the bottom.

Updated October 29, 2026. Lilly's October 28 release on its TRANSCEND-T2D-2 trial repeats that no regulator anywhere has approved retatrutide and that anyone selling it to consumers "is breaking the law." Its October 29 quarterly filing lists illegally compounded products among business risks. More: retatrutide vs. Ozempic. [V]

The gist

Telehealth companies, medical spas, weight-loss clinics and websites using "research use only" labels are all marketing products they say contain retatrutide. FDA, Lilly and CBS News have each documented this. [V]
No regulator anywhere has approved a medicine containing retatrutide, and FDA says it "cannot be used in compounding under federal law." [V]
FDA says it has warned telehealth companies over retatrutide marketing, and Lilly's court filings count at least 21 FDA warning letters tied to retatrutide. [V]
Lilly has filed 11 lawsuits against alleged sellers in two waves, on August 12 and October 8, 2026. These are allegations, not findings. [V]
The October 28 HHS peptide policy covers six other peptides. It doesn't touch retatrutide. [V]

11lawsuits Lilly has filed against alleged retatrutide sellers since August [V]
21+FDA warning letters tied to retatrutide, per Lilly's complaints [V]
14,000+listings, ads and posts Lilly says it has reported, across 100+ countries [V]
0regulators worldwide that have approved a retatrutide medicine [V]

Why the offers exist at all

Start with the science, because it's the reason for the rush. In Lilly's TRIUMPH-1 phase 3 trial, the highest-dose group lost an average of 28.3% of body weight over 80 weeks, against 2.2% on placebo. [V] That's a randomized, double-blind result in 2,339 adults, and it put retatrutide, which acts on three hormone receptors (GIP, GLP-1 and glucagon), at the top of the obesity-drug conversation. We cover the full trial record in our retatrutide explainer.

Approval is still ahead. Lilly says it plans to submit retatrutide to FDA in the first quarter of 2027. [V] That leaves a gap of a year or more between headline results and any legal prescription, and the market has rushed into it.

CBS News put it bluntly in August: "many telehealth firms, clinics and peptide vendors online have decided to offer the next-generation drug anyway." [S] A June CBS investigation identified several compounding pharmacies that had made imitation retatrutide. [S]

What's being offered, and by whom

The offers come in a few recognizable shapes, according to FDA, Lilly and court filings:

Telehealth platforms. FDA says it has warned telehealth companies "for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers." [V] FDA hasn't named those firms on its summary page, and we haven't found a reliable source naming a specific telehealth platform over retatrutide, so we don't name any here. [U]
Med spas and weight-loss clinics. Lilly is suing Aesthetic Envy, a California med spa; MedShape Weight Loss Clinic in Arizona; and Medrein Health & Aesthetics, a Southlake, Texas med spa. [V] Lilly alleges Medrein pitched its product to people who hadn't "reached their goals" on semaglutide or tirzepatide. [V]
A compounding pharmacy. Lilly sued Striker Pharmacy in the Southern District of Texas. CBS reported it had made a version of the drug. [V][S]
"Research use only" websites. Most of the remaining defendants are online peptide sellers. Lilly alleges their research disclaimers mask sales meant for human use. [V]

The defendants hadn't responded to CBS's requests for comment when it reported on the August suits, and several took down their retatrutide pages. [S] None of these claims has been decided by a court. [V]

Where retatrutide stands legally

Three facts settle most of the questions people ask.

It isn't approved. Lilly says no medicine containing retatrutide "has yet been approved for human use by any regulatory agency in the world." [V] FDA adds that no one has shown it to be safe and effective for any use. [V]

It can't be compounded. A 503A pharmacy can compound only with ingredients that have a USP monograph, sit inside an approved drug, or appear on FDA's 503A bulks list. Retatrutide meets none of those. FDA said so in a March 31, 2025 letter to the National Association of Boards of Pharmacy, which passed it on to state boards. [V] That's different from the shortage-era compounding of semaglutide and tirzepatide, both of which are ingredients in approved drugs. [V]

A prescription doesn't fix it. Law firm Buchanan Ingersoll & Rooney, writing on October 15, said businesses "should not assume that a prescription, professional license or supplier's certificate of analysis" resolves the problem. [S] A clinician in the loop doesn't turn an unapproved drug into a lawful one.

And the news that started this week's confusion? HHS's October 28 enforcement discretion policy covers BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. Retatrutide isn't on the list. [V] Our breakdown of the HHS policy and retatrutide walks through it.

Enforcement so far: a timeline

Retatrutide enforcement, from first letter to this week

Mar. 31, 2025FDA tells NABP retatrutide can't be compounded under 503A or 503B; NABP alerts state boards Apr. 3 [V]
Sept. 9, 2025FDA warning letter calls one online seller's retatrutide products "unapproved new drugs and misbranded drugs" [V]
Mar. 3, 2026FDA warns 30 telehealth companies over misleading compounded GLP-1 marketing (semaglutide and tirzepatide) [S]
Mar. 31, 2026FDA warning letters to three online sellers marketing retatrutide under names like "GLP-1-R" and "GLP-3 RT" [V]
June 15, 2026FDA updates its GLP-1 page: retatrutide can't be compounded; telehealth firms, ingredient distributors and outsourcing facilities warned [V]
Aug. 12, 2026Lilly files six lawsuits and says it has referred 200+ people and entities to regulators and law enforcement [V]
Oct. 8, 2026Lilly files five more suits, against three online sellers, a weight-loss clinic and a med spa [V]
Oct. 28, 2026HHS peptide compounding policy names six peptides; retatrutide not among them [V]

The March 2026 telehealth sweep is worth reading carefully. Those 30 letters dealt with compounded versions of approved GLP-1 drugs, not retatrutide, Reuters reported. [S] It still shows where FDA's attention sits: it cited firms for claiming compounded products matched approved drugs. [S]

The legal theories in Lilly's suits are a little unusual. None of them asks a court to enforce federal drug law directly. Against the online sellers, per the firm's summary [S], Lilly uses state unfair competition and consumer protection laws in eight states. Against the clinic and med spa, it uses false advertising claims under the federal Lanham Act. [S] Lilly is asking for permanent injunctions, money damages and fees. [S]

“What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk.” [V]

David A. Hyman, M.D., Lilly chief medical officer, Aug. 12, 2026

How to size up an offer: questions worth asking

These come straight from what FDA, Lilly and the court filings say. They aren't a verdict on any company. They're the questions the record raises.